News Center
Welcome to the McNeil Pediatrics™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc News Center. Here you'll find our latest press releases and corporate statements.
Press Releases
Following are recent news releases issued by McNeil Pediatrics™. |
Corporate Statements
Check here for updates on any McNeil Pediatrics statements. There are no statements at this time.
IMPORTANT SAFETY INFORMATION
Talk to your doctor for a proper diagnosis and treatment of ADHD. Only a doctor can decide whether medication is right for you or your child.
CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome.
Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional.
The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia.
See Full U.S. Prescribing Information and Medication Guide for CONCERTA®.
